Floatz logo

AFP-464

Breast Neoplasm

Tigris PharmaceuticalsSmall moleculePhase 2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
81/ 100

Competitive context

177 Active assets in the Breast Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
Merck Sharp & Dohme LLC
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB
Letrozole
Fujian Cancer Hospital
Phase 4BB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
Docetaxel
Universitas Airlangga
Phase 4BB

View all 50 →

Same molecule, other indications

AFP-464 is also rated in:

breast cancerDormant
C
Indicative ·
38 / 100
View asset →
ovarian carcinomaDormant
C
Indicative ·
38 / 100
View asset →
male breast carcinomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →